Kestra Medical Technologies (KMTS) Corporate presentation summary

Market opportunity and clinical need

• U.S. market opportunity estimated at $10B, with $1B currently accessible and $9B unpenetrated, targeting approximately 850,000 eligible patients annually.

• Sudden cardiac arrest (SCA) causes ~436,000 deaths per year in the U.S., with 73% occurring at home and 50% unwitnessed.

• First 90 days post-diagnosis present the highest SCA risk, with many patients left unprotected during mandatory ICD waiting periods.

• Recent clinical publications and studies involving over 40,000 patients support broader adoption and guideline updates for wearable cardioverter defibrillators (WCDs).

Product innovation and platform

• The ASSURE WCD system offers improved comfort, actionable insights, and high patient compliance, addressing previous compliance challenges.

• The Cardiac Recovery System integrates wearable devices, digital platforms, and patient-provider connectivity for at-home cardiac care.

• ACE-PAS study demonstrated 100% shock conversion, exceptionally low inappropriate shock rates, and expanded clinical utility in real-world use.

• Platform designed for extensibility, supporting new sensors and future clinical applications, including integration with FDA-cleared Biobeat sensor.

Commercial execution and growth

• Achieved over 290M covered lives under contract, representing ~90% of all covered lives in the U.S.

• Commercial team rapidly expanding, with sales territories projected to grow from 48 to 130 between FY24 and FY26.

• Focused sales efforts on high-prescribing hospitals and clinics, leveraging concentrated prescriber base.

• Rental and re-use business model enables attractive unit economics and scalability.